|

68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.

RECRUITINGPhase 2Sponsored by Peking Union Medical College Hospital
Actively Recruiting
PhasePhase 2
SponsorPeking Union Medical College Hospital
Started2024-03-27
Est. completion2026-09
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06613269

Summary

Radiation therapy (RT) is an effective treatment for patients with advanced-stage clear cell renal cell carcinoma (ccRCC). Current evidence has shown promising outcomes combining radiation therapy and standard systemic therapy in patients with metastatic/recurrent ccRCC. CAIX is a highly sensitive and specific biomarker expressed on ccRCC and in previous studies the investigators have shown excellent diagnostic efficacy of 68Ga-NY104, a CAIX-targeted PET tracer, in patients with metastatic ccRCC. In this study, the investigators aim to investigate the effect of 68Ga-NY104, and 18F-FDG PET/CT guided RT combining standard systemic therapy in patients with metastatic ccRCC.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥ 18 years old
* Histologically or cytologically confirmed clear cell renal cell carcinoma
* Eligible for radiation therapy: no more than 10 lesions in total
* Expected survival: over 3 months
* ECOG: 0 or 1
* Sufficient organ function
* Written informed consent

Exclusion Criteria:

* Brain metastasis/carcinomatous meningitis
* Other malignant tumors that are not controlled within 5 years, except for non-metastatic low-risk prostate cancer.
* Pregnant or breastfeeding.
* Active infection.

Conditions2

CancerClear Cell Renal Cell Carcinoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.